GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » Price-to-Operating-Cash-Flow

Innate Pharma (XPAR:IPH) Price-to-Operating-Cash-Flow : (As of Jun. 06, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma Price-to-Operating-Cash-Flow?

As of today (2024-06-06), Innate Pharma's share price is €2.555. Innate Pharma's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.41. Hence, Innate Pharma's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Innate Pharma's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 13 years, Innate Pharma's highest Price-to-Operating-Cash-Flow Ratio was 13.68. The lowest was 2.61. And the median was 3.87.

XPAR:IPH's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 25.87
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Innate Pharma's Cash Flow from Operations per share for the six months ended in Dec. 2023 was €-0.26. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.41.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 14.90% per year.

During the past 13 years, Innate Pharma's highest 3-Year average Operating Cash Flow per Share Growth Rate was 14.90% per year. The lowest was -34.70% per year. And the median was -5.70% per year.


Innate Pharma Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Innate Pharma's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Price-to-Operating-Cash-Flow Chart

Innate Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.42 - - - -

Innate Pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Innate Pharma's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Innate Pharma's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innate Pharma's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Innate Pharma's Price-to-Operating-Cash-Flow falls into.



Innate Pharma Price-to-Operating-Cash-Flow Calculation

Innate Pharma's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=2.555/-0.405
=

Innate Pharma's Share Price of today is €2.555.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innate Pharma's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.41.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Innate Pharma Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Innate Pharma (XPAR:IPH) Business Description

Industry
Traded in Other Exchanges
Address
117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (XPAR:IPH) Headlines

No Headlines